Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Ganaxolone in Status Epilepticus
NCT03350035Phase 2Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Sep 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of ganaxolone in status epilepticus (SE), sponsored by Marinus Pharmaceuticals. Started Feb 2018; status: completed.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT03350035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350035.